ABOUT SUVODA
Suvoda is a global clinical trial technology company whose real-time experience platform empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company maintains customer satisfaction scores that consistently exceed the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 2000 trials across more than 95 countries. Suvoda recently merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com. Follow Suvoda on LinkedIn.
-
Suvoda And Greenphire Announce Completion of Merger
Suvoda and Greenphire have announced the successful completion of their previously announced merger. Through this merger, the combined company is now better equipped to provide a comprehensive solution to its customers to support the urgent and mission critical moments of their clinical trials.
FEATURED ARTICLES
-
In 2026, clinical trial success depends on moving from AI hype to proven utility. Unified data and seamless site experiences are no longer optional; they are the keys to trial resilience.
-
As we look toward 2026, the conversation around clinical trial technology is shifting from simple digitization to true platform unification.
-
The solution to administrative burden in clinical trials is not in adding more tools, but in improved integration that allows software to fade into the background.
-
Simplify the clinical trial journey by unifying logistics, data, and payments. Reduce administrative friction for sites and improve the patient experience to accelerate trial timelines.
-
A unified patient app streamlines clinical trial participation by combining scheduling, questionnaires, travel, and payments—reducing burden, improving engagement, and supporting better retention and data quality.
-
Outdated budgeting slows oncology trials. Real-world site cost data enables faster planning, smoother startup, and better patient care through smarter, evidence-based financial decisions.
-
Accurate quality of life data is critical in oncology. eCOA unified with IRT streamlines trials, improves data collection, and enhances site user experiences across therapeutic areas.
-
Real-time eCOA data enables faster eligibility decisions, proactive issue alerts, and streamlined operations by unifying data, improving precision, responsiveness, and trial execution efficiency.
-
Clinical trials don’t have to be so complex. Jagath Wanninayake shares why focusing on time-sensitive moments—and not everything at once—can drive better outcomes and how a recent merger supports that shift.
-
Discover how streamlined clinical supply chain management helped accelerate study timelines, reduce costs, and support global treatment delivery through a strategic technology partnership.
CONTACT INFORMATION
Suvoda
181 Washington St., Suite 100
Conshohocken, PA 19428
UNITED STATES
NEWS
OUR PRODUCTS
ADDITIONAL PRODUCT INFORMATION
-
A single mobile app simplifies clinical trial participation by unifying eConsent, IRT, and eCOA workflows, reducing patient burden and improving engagement across trial phases and locations.
-
esigned for sponsors, CROs, sites, and patients, this modern solution delivers real-time data that supports crucial decisions during investigator grant budgeting, randomization, patient payments, and endpoint collection.
-
Streamline trial budgets and payments with real-time fair market data, speeding startups and ensuring timely, transparent site funding worldwide.
-
With the right IRT platform, you can handle inherent complexities and constant change, enabling confident decisions to move life-changing studies forward.